Panel on Clinical Practices for Treatment of HIV Infection convened
by the US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults
and adolescents. Available at: http://www.hivatis.org/trtgdlns.html. Accessibility
verified February 13, 2001.
Carpenter CC, Cooper DA, Fischl MA.
et al. Antiretroviral therapy in adults. JAMA.2000;283:381-390.
Pozniak A, Gazzard BG, Churchill D.
et al. British HIV association (BHIVA) guidelines for the treatment of HIV-infected
adults with antiretroviral therapy. Available at: http://www.aidsmap.com/bhiva. Accessibility
verified January 30, 2001.
Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med.1997;337:734-739.
Hammer S, Squires K, Hughes M.
et al. A controlled trial of two nucleoside analogues plus indinavir in persons
with human immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. N Engl J Med.1997;337:725-733.
Gulick RM, Mellors JW, Havlir D.
et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine,
and lamivudine for HIV-1 infection: 100-week follow-up. JAMA.1998;280:35-41.
Ledergerber B, Egger M, Opravil M.
et al. Clinical progression and virological failure on highly active antiretroviral
therapy in HIV-1 patients: a prospective cohort study. Lancet.1999;353:863-868.
Carr A, Samaras K, Burton S.
et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin
resistance in subjects receiving HIV protease inhibitors. AIDS.1998;12:F51-F58.
Carr A, Samaras K, Chisolm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy,
hyperlipidaemia, and insulin resistance. Lancet.1998;351:1881-1883.
Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS.1997;11:1665-1670.
Stone VE, Hirschhorn LR, Boswell SL.
et al. Discontinuation (D/C) of protease inhibitor (PI) therapy: reasons and
risk factors. From: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland.
Faletto MB, Miller WH, Garvery EP.
et al. Unique intracellular activation of the potent anti-HIV agent 1592U89. Antimicrob Agents Chemother.1997;41:1099-1107.
Daluge SM, Good SS, Faletto MB.
et al. 1592 succinate. Antimicrob Agents Chemother.1997;41:1082-1093.
Tisdale M, Alnadaf T, Cousens D. Combination of mutations in HIV-1 reverse transcriptase required for
resistance to carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother.1997;41:1094-1098.
Lanier R, Danehower S, Daluge S.
et al. Genotypic and phenotypic correlates of response to abacavir (ABC, 1592). Antivir Ther.1998;3(suppl):36.
Miller V, Ait-Khaled M, Stone C.
et al. HIV-1 reverse transcriptase genotype and susceptibility to RT inhibitors
during abacavir monotherapy and combination therapy. AIDS.2000;14:163-171.
Harrigan PR, Stone C, Griffin P.
et al. Resistance profile of the human immunodeficiency virus type 1 reverse
transcriptase inhibitor abacavir (1592U89) after monotherapy and combination
therapy. J Infect Dis.2000;181:912-920.
Saag MS, Sonnerborg A, Torres RA.
et al. Antiretroviral effect and safety of abacavir alone and in combination
with zidovudine in HIV-infected adults. AIDS.1998;12:F203-F209.
Staszewski S, Katlama C, Harrer T.
et al. A dose-ranging study to evaluate the safety and efficacy of abacavir
alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive
Fischl M, Greenberg S, Clumeck N.
et al. Ziagen (Abacavir, ABC, 1592) combined with 3TC & ZDV is highly
effective and durable through 48 weeks in HIV-1 infected antiretroviral-naïve
subjects (CNAB3003). From: Sixth Conference on Retroviruses and Opportunistic Infection;
January 31-February 4, 1999; Chicago, Ill. Abstract 19.
1993 revised classification system for HIV infection and expanded surveillance
case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep.1992;41(RR-17):1-19.
Division of AIDS. Division of AIDS Table for Grading Severity of Adult
Adverse Experiences. Rockville, Md: National Institute of Allergy and Infectious Diseases;
Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated
DNA sequencing. Nature.1993;365:671-673.
Raboud JM, Montaner JSG, Conway B.
et al. Suppression of plasma viral load below 20 copies/mL is required to
achieve a long-term response to therapy. AIDS.1998;12:1619-1624.
Eudra Web site. Points to consider on switching between superiority and non-inferiority. Available at: http://www.eudra.org. Accessibility verified
February 6, 2001.
Borenstein M. The case for confidence intervals in controlled clinical trials. Control Clin Trials.1994;15:411-418.
Goodgame JC, Pottage JC, Jablonowski H.
et al. Amprenavir in combination with lamivudine and zidovudine versus lamivudine
and zidovudine alone in HIV-infected antiretroviral-naïve adults. Antivir Ther.2000;5:215-225.
Murphy RL, Katlama C, Johnson V.
et al. The Atlantic study: a randomized, open-label trial comparing two protease
inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing
regimen, 48 week data. From: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy;
September 1999; San Francisco, Calif. Abstract LB-22.
Squires KE, Gulick R, Tebas P.
et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine
in combination with indinavir in antiretroviral naïve individuals with
HIV infection. AIDS.2000;14:1591-1600.
Staszewski S, Morales-Ramirez J, Tashima KT.
et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir,
and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection
in adults. N Engl J Med.1999;341:1865-1873.
Descamps D, Flandre P, Calvez V.
et al. Mechanisms of virologic failure in previously untreated HIV-infected
patients from a trial of induction-maintenance therapy. JAMA.2000;283:205-211.
Havlir D, Nellamnn NS, Petropoulos CJ.
et al. Drug susceptibility in HIV infection after viral rebound in patients
receiving indinavir-containing regimens. JAMA.2000;283:229-234.
Maguire M, Gartland M, Moore S.
et al. Absence of zidovudine resistance in antiretroviral-naïve patients
following zidovudine/lamivudine/protease inhibitor combination therapy. AIDS.2000;14:1195-1201.
Kempf DJ, Rode RA, Xu Y.
et al. The duration of viral suppression during protease inhibitor therapy
for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS.1998;12:F9-F14.
Raboud JM, Rae S, Hogg RS.
et al. Suppression of plasma viral load to below the detection limit of human
immunodeficiency virus kit is associated with longer virologic response than
suppression below the limit of quantitation. J Infect Dis.1999;180:1347-1350.
Casado JL, Perez-Elias MJ, Antela A.
et al. Predictors of long-term response to protease inhibitor therapy in a
cohort of HIV-infected patients. AIDS.1998;12:F131-F135.
Deeks SG, Hecht FM, Swanson M.
et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in
an urban AIDS clinic. AIDS.1999;13:F35-F43.
Hetherington S, Steel H, Naderer O.
et al. Hypersensitivity reactions during therapy with abacavir. From: 7th Conference on Retroviruses and Opportunistic Infections.
January 30-February 2, 2000; San Francisco, Calif. Abstract 60.
Harrington M, Carpenter CCJ. Hit HIV-1 hard, but only when necessary. Lancet.2000;355:2147-2152.
Moyle GJ. Considerations in the choice of protease inhibitor-sparing regimens
in initial therapy for HIV-1 infection. Curr Opin Infect Dis.2000;13:19-25.